|
Genaera Corporation announced today a poster presentation of preclinical data on trodusquemine (MSI-1436), Genaera’s lead drug candidate for the treatment of type 2 diabetes and obesity, during the Diabetes Mellitus, Insulin Action and Resistance Keystone Symposia in Breckenridge, Colorado
PLYMOUTH MEETING, PA, USA | January 24, 2008 | Genaera Corporation (NASDAQ:GENR) announced today a poster presentation of preclinical data on trodusquemine (MSI-1436), Genaera’s lead drug candidate for the treatment of type 2 diabetes and obesity, during the Diabetes Mellitus, Insulin Action and Resistance Keystone Symposia in Breckenridge, Colorado.
Genaera research scientists concluded that treatment with MSI-1436 leads to marked improvement in glucose tolerance and lowers plasma insulin levels in diet-induced obese (DIO) mice and improves fasting blood glucose and glucose tolerance in hyperglycemic animal models, and that these effects are maintained over time. In one study, the researchers reported that four weekly treatments of MSI-1436 administered to DIO mice resulted in significant reductions in plasma insulin levels. Additionally, hyperglycemic (Ob/Ob) mice treated with weekly doses of MSI-1436 for 122 days demonstrated that the significant improvements in glucose tolerance, as measured by oral glucose tolerance testing can be sustained during long periods of therapy. The scientists concluded that the anti-diabetic properties of MSI-1436 included improved insulin sensitivity, lowering of plasma insulin levels and durable improvements in fasting blood glucose and glucose tolerance.
“This encouraging preclinical work continues to provide strong basic science support and direction for our efforts to explore MSI-1436 as a therapy for type 2 diabetes,” stated Jack Armstrong, President and Chief Executive Officer of Genaera. “With our recent investigational new drug (IND) filing for type 2 diabetes now in effect and the positive metabolic data from our first completed Phase 1 study in obesity, we are executing upon our strategy to evaluate the potential of MSI-1436 to impact both type 2 diabetes and obesity.”
The poster entitled “Trodusquemine (MSI-1436) Enhances Glucose Tolerance in a Murine Model of Insulin Resistance” will be displayed from 7:30 p.m. to 10:00 p.m. MT at the Beaver Run Resort in Breckenridge, Colorado.
About Trodusquemine (MSI-1436)
Trodusquemine is a centrally and peripherally-acting appetite suppressant and the first highly selective inhibitor of protein tyrosine phosphatase 1B (PTP-1B). PTP-1B is central to controlling the function of both the leptin and insulin pathways. By inhibiting PTP-1B, MSI-1436 is expected to decrease appetite and normalize blood sugar. Trodusquemine has produced consistent, sustainable weight loss in a variety of animal models and appears to overcome metabolic readjustment, which often limits sustained weight loss during caloric restriction. In addition, trodusquemine has shown the ability to reverse comorbidities associated with obesity such as abnormal glucose metabolism and cholesterol elevation.
About Genaera
Genaera Corporation is focused on advancing the science and treatment of metabolic diseases. The Company has significant market opportunities with a first-in-class molecule, trodusquemine (MSI-1436), that has the potential to redefine the treatment paradigm for obesity and type 2 diabetes and is presently in a Phase 1 trial in obesity. In addition, Genaera has a value-driven, fully out-licensed partnership with MedImmune, Inc. for a second core program that is presently undergoing Phase 2 clinical testing in asthma. Genaera is committed to directing resources to its core program and the aggressive clinical development of its key assets to build stockholder value. For further information, please see our website at http://www.genaera.com.
SOURCE: Genaera |
